alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['I1171N'],"[{'ncitCode': 'C101790', 'drugName': 'Alectinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['29376144', '23239810', '29650534', '25393798', '25393796', '27565911', '25736571']",[],"Alectinib is a second-generation small molecule inhibitor of ALK. Across various studies, five patients with ALK fusion-positive non-small cell lung cancer (NSCLC) have acquired ALK I1171N mutations upon disease progression with alectinib treatment (PMID: 25393796, 25393798, 27565911, 29376144, 23239810, 25736571). Additionally, in vitro data has shown that cells harboring the ALK I1171N mutation are resistant to alectinib as measured by clinically unachievable IC50 (PMID: 29650534)."
